Algert Global LLC Xenon Pharmaceuticals Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Algert Global LLC holds 219,645 shares of XENE stock, worth $8.41 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

219,645

Previous 183,205 19.89%

Holding current value

$8.41 Million

Previous $7.14 Million 21.06%

% of portfolio

0.23%

Previous 0.24%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$36.12 - $43.96 $1.32 Million - $1.6 Million	36,440 Added 19.89%	219,645 $8.65 Million
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $29,362 - $35,437	-810 Reduced 0.44%	183,205 $7.14 Million
Q1 2024 May 14, 2024	SELL	$42.66 - $50.04 $1.42 Million - $1.67 Million	-33,305 Reduced 15.33%	184,015 $7.92 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $2.55 Million - $4.13 Million	88,833 Added 69.14%	217,320 $10 Million
Q3 2023 Nov 13, 2023	SELL	$34.16 - $39.73 $559,882 - $651,174	-16,390 Reduced 11.31%	128,487 $4.39 Million
Q2 2023 Aug 14, 2023	BUY	$34.84 - $43.54 $3.71 Million - $4.64 Million	106,470 Added 277.22%	144,877 $5.58 Million
Q1 2023 May 12, 2023	BUY	$33.46 - $40.35 $66,618 - $80,336	1,991 Added 5.47%	38,407 $1.38 Million
Q4 2022 Feb 13, 2023	SELL	$33.06 - $39.43 $291,919 - $348,166	-8,830 Reduced 19.52%	36,416 $1.44 Million
Q3 2022 Nov 15, 2022	BUY	$30.79 - $39.82 $580,145 - $750,288	18,842 Added 71.36%	45,246 $1.63 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $364,555 - $503,842	14,330 Added 118.68%	26,404 $803,000
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $302,936 - $400,011	12,074 New	12,074 $369,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Xenon Pharmaceuticals Inc. Transaction History